Vertex Pharmaceuticals Incorporated Share Price & Technical Analysis
VRTX · $428.3 (+0.76%)
Healthcare / Biotechnology
$428.3
+0.76%
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF…
Price chart
Seasonality
Jun has 4 positive and 1 negative years (last 5 years shown)
-3% return in Jun, 4% avg return in past 3 year Jun month.
-2% return in 2026, 18% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 3% | 6% | -10% | -5% | 5% | -3% | – | – | – | – | – | – | -2% |
| 25 | 15% | 4% | 1% | 5% | -13% | 1% | 3% | -15% | 0% | 8% | 1% | 5% | 15% |
| 24 | 7% | -3% | -1% | -7% | 16% | 3% | 6% | 0% | -6% | 1% | -1% | -14% | 2% |
| 23 | 12% | -10% | 9% | 8% | -5% | 8% | 1% | -1% | -1% | 4% | -3% | 15% | 38% |
| 22 | 11% | -5% | 14% | 4% | 2% | 2% | 0% | 1% | 3% | 6% | 1% | -9% | 30% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$108.26B
P/E ratio
25.35
52W high
$507.9
52W low
$362.5
Volume
13,24,326
Beta
0.30
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹34,400
Abbott Laboratories Cede…
₹32,740
Eli Lilly And Company Ce…
₹28,720
Unitedhealth Group Inc C…
₹17,140
Elevance Health Inc
₹6,770
Frequently asked questions
- What is Vertex Pharmaceuticals Incorporated share price today?
- Vertex Pharmaceuticals Incorporated (VRTX) last traded around $428.3 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does VRTX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for VRTX. Download the app for real-time alerts.
- How can I analyze Vertex Pharmaceuticals Incorporated stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.